Cost per month of overall survival and progression-free survival: everolimus compared with cabozantinib, nivolumab, and axitinib for metastatic renal cell carcinoma
BJU INTERNATIONAL(2016)
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined